Inspire Medical Systems, Inc. (INSP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INSP SEC filings page.
Inspire Medical Systems, Inc. (INSP) reported $898.7M in revenue over the twelve months to Jun 30, 2026, up 4.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue growth is now translating into operating profit, but FY2025 earnings were lifted beyond operations by a large tax benefit.
The main earnings-quality wrinkle is that FY2025 net income reached$145M while operating income was only$51M . That gap is largely explained by-$80M of reported income-tax expense, so the year's net result includes a substantial tax benefit rather than operating gains alone.
Revenue reached
Operating cash flow was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Inspire Medical Systems, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Inspire Medical Systems, Inc. has an operating margin of 5.6%, meaning the company retains $6 of operating profit per $100 of revenue. This results in a moderate score of 37/100, indicating healthy but not exceptional operating efficiency. This is up from 4.5% the prior year.
Inspire Medical Systems, Inc.'s revenue grew 13.6% year-over-year to $912.0M, a solid pace of expansion. This earns a growth score of 83/100.
Inspire Medical Systems, Inc. carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 77/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.08, Inspire Medical Systems, Inc. holds $6.08 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 94/100.
Inspire Medical Systems, Inc. has a free cash flow margin of 8.6%, earning a moderate score of 58/100. The company generates positive cash flow after capital investments, but with room for improvement.
Inspire Medical Systems, Inc.'s ROE of 18.6% shows moderate profitability relative to equity, earning a score of 35/100. This is up from 7.8% the prior year.
Inspire Medical Systems, Inc. scores 11.08, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.0B) relative to total liabilities ($126.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Inspire Medical Systems, Inc. passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Inspire Medical Systems, Inc. generates $0.80 in operating cash flow ($117.0M OCF vs $145.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Inspire Medical Systems, Inc. earns $371.93 in operating income for every $1 of interest expense ($51.0M vs $137K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Inspire Medical Systems, Inc. generated $200.6M in revenue in Q2 2026. This represents a decrease of 7.6% from the same quarter a year earlier. Against the prior quarter it is down 2.0%.
Inspire Medical Systems, Inc.'s EBITDA was $4.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 4764.3% from the same quarter a year earlier. Against the prior quarter it is up 2.4%.
Inspire Medical Systems, Inc. reported $314K in net income in Q2 2026. This represents an increase of 108.7% from the same quarter a year earlier. Against the prior quarter it is up 102.8%.
Inspire Medical Systems, Inc. earned $0.01 per diluted share (EPS) in Q2 2026. This represents an increase of 108.3% from the same quarter a year earlier. Against the prior quarter it is up 102.6%.
Cash & Balance Sheet
Inspire Medical Systems, Inc. generated $14.1M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 322.8% from the same quarter a year earlier. Against the prior quarter it is up 350.5%.
Inspire Medical Systems, Inc. held $127.8M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Inspire Medical Systems, Inc.'s gross margin was 85.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.0 percentage points.
Inspire Medical Systems, Inc.'s operating margin was -0.3% in Q2 2026, reflecting core business profitability. This is up 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.3 percentage points.
Inspire Medical Systems, Inc.'s net profit margin was 0.2% in Q2 2026, showing the share of revenue converted to profit. This is up 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.7 percentage points.
Inspire Medical Systems, Inc.'s ROE was 0.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.5 percentage points.
Capital Allocation
Inspire Medical Systems, Inc. invested $24.7M in research and development in Q2 2026. This represents a decrease of 5.8% from the same quarter a year earlier. Against the prior quarter it is down 4.4%.
Inspire Medical Systems, Inc. repurchased no shares in Q2 2026.
Inspire Medical Systems, Inc. invested $9.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 1.8% from the same quarter a year earlier. Against the prior quarter it is down 5.8%.
INSP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $200.6M-7.6% | $204.6M+1.6% | $269.1M+12.2% | $224.5M+10.5% | $217.1M+10.8% | $201.3M+22.7% | $239.7M+24.5% | $203.2M+32.5% |
| Cost of Revenue | $29.1M-16.0% | $27.7M-9.9% | $36.1M+0.2% | $31.8M-1.9% | $34.7M+16.2% | $30.7M+24.0% | $36.0M+28.3% | $32.4M+32.9% |
| Gross Profit | $171.5M-6.0% | $176.9M+3.7% | $233.0M+14.4% | $192.7M+12.8% | $182.4M+9.9% | $170.6M+22.5% | $203.7M+23.9% | $170.8M+32.5% |
| R&D Expenses | $24.7M-5.8% | $25.8M-7.1% | $24.9M-17.8% | $24.2M-7.2% | $26.2M-9.2% | $27.8M-3.6% | $30.3M-2.3% | $26.1M-10.5% |
| SG&A Expenses | $147.3M-7.7% | $152.2M+5.5% | $162.0M+14.4% | $158.9M+21.8% | $159.5M+20.8% | $144.3M+14.9% | $141.5M+14.0% | $130.4M+15.1% |
| Operating Income | -$514K+84.5% | -$1.1M+24.7% | $46.1M+44.6% | $9.6M-32.6% | -$3.3M-165.0% | -$1.5M+90.2% | $31.9M+242.9% | $14.3M+206.3% |
| EBITDA | $4.1M+4764.3% | $4.0M+156.1% | $49.9M+45.6% | $13.3M-17.7% | $84K-98.7% | $1.6M+110.8% | $34.3M+241.2% | $16.2M+228.0% |
| Interest Expense | N/A | N/A | N/A | $11K | $4K | N/A | N/A | $0 |
| Income Tax | $2.8M+122.3% | $13.7M+1073.2% | -$85.8M-6174.4% | $3.6M+97.9% | $1.3M+19.7% | $1.2M+79.5% | $1.4M+196.0% | $1.8M+437.9% |
| Net Income | $314K+108.7% | -$11.3M-477.5% | $136.1M+286.4% | $9.9M-46.3% | -$3.6M-136.7% | $3.0M+129.9% | $35.2M+138.6% | $18.5M+316.6% |
| EPS (Basic) | $0.01+108.3% | -$0.39-490.0% | $4.63+289.1% | $0.34-45.2% | -$0.12-136.4% | $0.10+129.4% | $1.19+133.3% | $0.62+313.8% |
| EPS (Diluted) | $0.01+108.3% | -$0.39-490.0% | $4.58+298.3% | $0.34-43.3% | -$0.12-137.5% | $0.10+129.4% | $1.15+125.5% | $0.60+306.9% |
| Diluted Shares (Avg) | 29M-1.9% | 29M-5.3% | N/A | 30M-3.4% | 30M-3.0% | 30M+2.4% | N/A | 31M+4.3% |
INSP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $926.0M+15.4% | $911.4M+24.7% | $907.3M+12.2% | $807.7M+1.4% | $802.2M+10.1% | $730.8M+6.6% | $808.4M+19.4% | $796.2M+24.5% |
| Current Assets | $608.7M+6.2% | $566.8M-0.9% | $583.7M-7.5% | $586.5M+0.7% | $573.2M-5.6% | $571.7M-0.1% | $630.8M+6.2% | $582.5M+2.3% |
| Cash & Equivalents | $127.8M+19.5% | $98.9M+83.6% | $104.8M-30.2% | $112.8M-23.5% | $106.9M-43.1% | $53.9M-69.3% | $150.2M-19.1% | $147.5M-55.3% |
| Short-Term Investments | $192.9M-0.5% | $184.9M-41.4% | $203.5M-31.1% | $209.7M-20.4% | $194.0M-22.9% | $315.3M+18.6% | $295.4M+7.5% | $263.5M+96.2% |
| Inventory | $170.5M+40.1% | $166.2M+66.7% | $145.3M+81.3% | $141.8M+110.3% | $121.6M+106.1% | $99.7M+103.6% | $80.1M+136.4% | $67.4M+158.2% |
| Accounts Receivable | $103.3M-24.9% | $105.1M+13.5% | $119.7M+28.6% | $108.0M+20.3% | $137.7M+72.7% | $92.6M+28.1% | $93.1M+3.5% | $89.7M+25.6% |
| Long-Term Investments | $94.5M-14.0% | $115.9M+158.5% | $96.3M+35.7% | $88.4M-22.1% | $109.8M+316.9% | $44.8M+61.2% | $71.0M+676.5% | $113.4M+3730.6% |
| Total Liabilities | $100.4M-19.3% | $119.0M+25.2% | $126.2M+6.3% | $141.3M+41.8% | $124.4M+37.7% | $95.1M-1.8% | $118.7M+13.8% | $99.6M+4.5% |
| Current Liabilities | $71.2M-23.8% | $89.4M+40.9% | $96.1M+8.5% | $110.8M+49.3% | $93.4M+42.2% | $63.5M-12.1% | $88.5M+13.3% | $74.3M+6.1% |
| Non-Current Liabilities | $29.2M-5.8% | $29.6M-6.3% | $30.1M-0.3% | $30.4M+19.9% | $31.0M+25.8% | $31.6M+28.2% | $30.2M+15.3% | $25.4M+0.2% |
| Total Equity | $825.6M+21.8% | $792.3M+24.6% | $781.2M+13.3% | $666.5M-4.3% | $677.8M+6.2% | $635.7M+7.9% | $689.7M+20.5% | $696.6M+28.0% |
| Retained Earnings | -$157.5M+46.2% | -$157.8M+45.4% | -$146.5M+49.8% | -$282.6M+13.6% | -$292.5M+15.4% | -$288.9M+18.7% | -$291.9M+15.5% | -$327.1M+9.2% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
INSP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $23.2M+765.4% | $12.8M+291.7% | $52.5M-24.2% | $68.5M+31.1% | $2.7M+3541.0% | -$6.7M-175.7% | $69.2M+300.7% | $52.3M+1337.1% |
| Depreciation & Amortization | $4.6M+35.3% | $5.1M+67.9% | $3.8M+54.2% | $3.7M+94.7% | $3.4M+142.9% | $3.0M+262.8% | $2.5M+203.3% | $1.9M+137.5% |
| Stock-Based Compensation | $31.2M-25.2% | $30.7M-1.2% | N/A | $29.5M+4.6% | $41.7M+29.1% | $31.1M+18.0% | N/A | $28.2M |
| Capital Expenditures | $9.2M+1.8% | $9.7M+15.7% | $10.7M+51.6% | $10.4M+30.4% | $9.0M-27.4% | $8.4M-28.1% | $7.0M-12.5% | $8.0M+14.6% |
| Free Cash Flow | $14.1M+322.8% | $3.1M+120.7% | $41.8M-32.7% | $58.1M+31.2% | -$6.3M+49.4% | -$15.1M-432.8% | $62.2M+573.1% | $44.3M+1421.7% |
| Investing Cash Flow | $3.5M-92.4% | -$11.2M-624.3% | -$11.9M-416.9% | -$11.6M+88.7% | $46.6M+728.5% | -$1.6M+92.1% | $3.8M+102.5% | -$103.0M+28.6% |
| Financing Cash Flow | $1.9M-48.3% | -$7.5M+91.5% | -$48.3M+31.1% | -$51.1M-616.5% | $3.7M-47.8% | -$87.8M-11527.1% | -$70.1M-593.4% | $9.9M+182.6% |
| Share Buybacks | $0 | $0-100.0% | $50.0M | $50.0M | $0 | $75.0M | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
INSP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.5%+1.4pp | 86.5%+1.7pp | 86.6%+1.6pp | 85.9%+1.8pp | 84.0%-0.7pp | 84.8%-0.2pp | 85.0%-0.4pp | 84.1%0.0pp |
| Operating Margin | -0.3%+1.3pp | -0.5%+0.2pp | 17.1%+3.8pp | 4.3%-2.7pp | -1.5%-4.1pp | -0.7%+8.5pp | 13.3%+8.5pp | 7.0%+15.8pp |
| Net Margin | 0.2%+1.8pp | -5.5%-7.0pp | 50.6%+35.9pp | 4.4%-4.7pp | -1.7%-6.7pp | 1.5%+7.6pp | 14.7%+7.0pp | 9.1%+14.7pp |
| Return on Equity | 0.0%+0.6pp | -1.4%-1.9pp | 17.4%+12.3pp | 1.5%-1.2pp | -0.5%-2.1pp | 0.5%+2.2pp | 5.1%+2.5pp | 2.7%+4.2pp |
| Return on Assets | 0.0%+0.5pp | -1.2%-1.7pp | 15.0%+10.6pp | 1.2%-1.1pp | -0.4%-1.8pp | 0.4%+1.9pp | 4.4%+2.2pp | 2.3%+3.7pp |
| Current Ratio | 8.55+2.4x | 6.34-2.7x | 6.08-1.1x | 5.29-2.6x | 6.14-3.1x | 9.01+1.1x | 7.13-0.5x | 7.84-0.3x |
| Debt-to-Equity | 0.12-0.1x | 0.150.0x | 0.160.0x | 0.21+0.1x | 0.180.0x | 0.150.0x | 0.170.0x | 0.140.0x |
| Asset Turnover | 0.22-0.1x | 0.22-0.1x | 0.300.0x | 0.280.0x | 0.270.0x | 0.280.0x | 0.300.0x | 0.260.0x |
| FCF Margin | 7.0%+9.9pp | 1.5%+9.0pp | 15.5%-10.4pp | 25.9%+4.1pp | -2.9%+3.5pp | -7.5%-5.8pp | 25.9%+21.1pp | 21.8%+24.0pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. INSP | FY2025 | $912.0M | $145.4M | 16.0% | $2.0B | 64/100 |
| Alphatec Holdings, Inc. ATEC | FY2025 | $764.2M | -$143.4M | -18.8% | $1.6B | 35/100 |
| Haemonetics Corporation HAE | FY2026 | $1.3B | $97K | 0.0% | $5.4B | 58/100 |
| PROCEPT BioRobotics Corporation PRCT | FY2025 | $308.1M | -$96K | 0.0% | $1.1B | 54/100 |
| QuidelOrtho Corporation QDEL | FY2025 | $2.7B | -$1.1B | -41.4% | $920.3M | 23/100 |
| LivaNova PLC LIVN | FY2025 | $1.4B | -$242.5M | -17.5% | $4.2B | 59/100 |
Where Inspire Medical Systems, Inc. Ranks
Frequently Asked Questions
What is Inspire Medical Systems, Inc.'s annual revenue?
Inspire Medical Systems, Inc. (INSP) reported $912.0M in total revenue for fiscal year 2025. This represents a 13.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Inspire Medical Systems, Inc.'s revenue growing?
Inspire Medical Systems, Inc. (INSP) revenue grew by 13.6% year-over-year, from $802.8M to $912.0M in fiscal year 2025.
Is Inspire Medical Systems, Inc. profitable?
Yes, Inspire Medical Systems, Inc. (INSP) reported a net income of $145.4M in fiscal year 2025, with a net profit margin of 16.0%.
What is Inspire Medical Systems, Inc.'s EBITDA?
Inspire Medical Systems, Inc. (INSP) had EBITDA of $64.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Inspire Medical Systems, Inc.'s gross margin?
Inspire Medical Systems, Inc. (INSP) had a gross margin of 85.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Inspire Medical Systems, Inc.'s operating margin?
Inspire Medical Systems, Inc. (INSP) had an operating margin of 5.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Inspire Medical Systems, Inc.'s net profit margin?
Inspire Medical Systems, Inc. (INSP) had a net profit margin of 16.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Inspire Medical Systems, Inc.'s return on equity (ROE)?
Inspire Medical Systems, Inc. (INSP) has a return on equity of 18.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Inspire Medical Systems, Inc.'s free cash flow?
Inspire Medical Systems, Inc. (INSP) generated $78.5M in free cash flow during fiscal year 2025. This represents a -13.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Inspire Medical Systems, Inc.'s operating cash flow?
Inspire Medical Systems, Inc. (INSP) generated $117.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Inspire Medical Systems, Inc.'s total assets?
Inspire Medical Systems, Inc. (INSP) had $907.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Inspire Medical Systems, Inc.'s capital expenditures?
Inspire Medical Systems, Inc. (INSP) invested $38.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Inspire Medical Systems, Inc. spend on research and development?
Inspire Medical Systems, Inc. (INSP) invested $103.2M in research and development during fiscal year 2025.
What is Inspire Medical Systems, Inc.'s current ratio?
Inspire Medical Systems, Inc. (INSP) had a current ratio of 6.08 as of fiscal year 2025, which is generally considered healthy.
What is Inspire Medical Systems, Inc.'s debt-to-equity ratio?
Inspire Medical Systems, Inc. (INSP) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Inspire Medical Systems, Inc.'s return on assets (ROA)?
Inspire Medical Systems, Inc. (INSP) had a return on assets of 16.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Inspire Medical Systems, Inc.'s P/E ratio?
Inspire Medical Systems, Inc. (INSP) trades at 14.7x earnings, its market capitalization divided by net income of $135.0M net income, trailing 12 months to June 30, 2026. The market capitalization is $2.0B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Inspire Medical Systems, Inc.'s price-to-sales ratio?
Inspire Medical Systems, Inc. (INSP) trades at 2.2x sales, its market capitalization divided by revenue of $898.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.0B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Inspire Medical Systems, Inc.'s Altman Z-Score?
Inspire Medical Systems, Inc. (INSP) has an Altman Z-Score of 11.08, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Inspire Medical Systems, Inc.'s Piotroski F-Score?
Inspire Medical Systems, Inc. (INSP) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Inspire Medical Systems, Inc.'s earnings high quality?
Inspire Medical Systems, Inc. (INSP) has an earnings quality ratio of 0.80x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Inspire Medical Systems, Inc. cover its interest payments?
Inspire Medical Systems, Inc. (INSP) has an interest coverage ratio of 371.93x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Inspire Medical Systems, Inc.?
Inspire Medical Systems, Inc. (INSP) scores 64 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.